Use of Arterio-venous Fistula as First Choice for Intravenous Drug Administration in Kidney Transplant Recipients

Evaluate the Risks of Using Arteriovenous Fistula as First Choise for Drug Administration Clinical Trial

— PerFAV  

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02874391
• Other study ID #: PHRIP-15-633
• Status: Recruiting
• Phase: N/A
• First received: August 17, 2016
• Last updated: January 19, 2017
• Start date: September 2016
• Est. completion date: September 2019

Study information

• Verified date: January 2017
• Source: University Hospital, Angers
• Contact: Christelle Roux
• Email: Christelle.Roux[@]chu-angers.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Use of arteriovenous fistula for IV drug administration is controversial and often prohibited by nephrologists. However, we have been using this method in our department for years now in order to keep the patients 'veins for other fistulas in the future. The aim of this study is to evaluate our practice and maybe provide a justification for a larger multi-center study given the importance of this subject in patients with chronic renal failure.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: September 2019
• Est. primary completion date: September 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years, functional AV fistula, new kidney transplant recipient

Exclusion Criteria:

• Prothetic AV fistula, Very recent AV fistula of less than 3 months

Related Conditions & MeSH terms

• Arteriovenous Fistula
• Evaluate the Risks of Using Arteriovenous Fistula as First Choise for Drug Administration
• Fistula

Locations

Country	Name	City	State
France	CHU Angers	Angers

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Angers

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the risk of complications of AV fistula		12 months